VISITECT CD4 development update

Omega Diagnostics Group PLC

("Omega" or "the Company" or the "Group")

VISITECT® CD4 development update

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update with its VISITECT® CD4 development programme.

Further to the announcement on 10 April 2018, the Company recently held a design review meeting for its VISITECT® CD4 test for identifying advanced HIV disease*. The Company confirms that results from feasibility testing show acceptable performance against design goals and accordingly, the Company has progressed into a formal optimisation phase within its design control programme.

Colin King, CEO of Omega commented: "I am pleased to report we have achieved this key milestone as promised and that our product aligns with our design specifications. This enhancement to our 350 test line is crucial in managing patients with advanced diseases and one that the NGO community are keen to see brought to the market. I look forward to making further announcements as we bring this product to market."

* defined as those patients with lower than 200 CD4+ T cells per microlitre of blood

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts: